IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: The rate of responses in the Imatinib-peg-IFN arm was comparable to the responses obtained with the second generation inhibitors nilotinib and dasatinib.15,16 In the German CML IV randomized study,25 1104 newly diagnosed CML patients in chronic phase were randomized to receive imatinib 800mg/d (n=338), imatinib 400mg/d (n=325), or imatinib 400mg/d plus interferon alfa (IFN- α; n=351).